Clinical Trial

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Staff December 19, 2023

BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical...

Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Staff December 19, 2023

NORSE EIGHT study on track to commence in Q1 2024Resubmission of ONS-5010 Biologics License Application (BLA) in the U.S. expected...

Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program

Staff December 19, 2023

SYDNEY, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new...

Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform

Staff December 19, 2023

Patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tractSAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics,...

23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts

Staff December 19, 2023

Thirty additional patients with advanced neuroendocrine and advanced ovarian cancer will be enrolled in the study of 23ME-00610, an investigational...

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

Staff December 19, 2023

RMAT designation intended to help expedite development of new regenerative medicines MALVERN, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc....

BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network

Staff December 19, 2023

BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...

Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease

Staff December 19, 2023

NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

Staff December 19, 2023

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel...

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Staff December 19, 2023

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to...

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

Staff December 19, 2023

PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on...

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

Staff December 19, 2023

– Results published in JACI: In Practice show rapid and sustained reductions in HAE attacks and improved quality of life...

Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF

Staff December 19, 2023

TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage...

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

Staff December 19, 2023

SUNNYVALE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the treatment...

FamGenix and Spesana Announce Strategic Partnership to Advance Patient Care Workflow Solutions & Integrate Hereditary Risk Screening

Staff December 18, 2023

DELRAY BEACH, Fla. & MEMPHIS, Tenn.--(BUSINESS WIRE)--FamGenix and Spesana, two leading health-tech companies, are thrilled to announce a strategic partnership...

IAVI and Zendal Announce Funding for Efficacy Trial of Promising TB Vaccine Candidate in Africa

Staff December 18, 2023

TB kills 1.3 million people a year and sickens more than 10 million people annually.A new TB vaccine is needed...

A Letter From Cannabis Bioscience International Holdings CEO Dante Picazo Regarding Actual Progress and Plans for 2024

Staff December 18, 2023

Houston, Texas--(Newsfile Corp. - December 18, 2023) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH). CEO Dante Picazo sending...

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Staff December 18, 2023

Independent DSMB recommends continuing clinical trial of Berubicin without modificationEnrollment expected to be complete in early Q1 2024HOUSTON, TX /...

Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease

Staff December 18, 2023

ANN ARBOR, MI / ACCESSWIRE / December 18, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...

Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024

Staff December 16, 2023

LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on...

Clinical Trial

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program

Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform

23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network

Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

FamGenix and Spesana Announce Strategic Partnership to Advance Patient Care Workflow Solutions & Integrate Hereditary Risk Screening

IAVI and Zendal Announce Funding for Efficacy Trial of Promising TB Vaccine Candidate in Africa

A Letter From Cannabis Bioscience International Holdings CEO Dante Picazo Regarding Actual Progress and Plans for 2024

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease

Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024

Defence’s Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio with Ellis Martin

Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

The WISH Clinic Partnering With Clara Care to Bring Specialized Wound Care Directly to Patients in the Convenience of Their Homes

You may have missed